Category: 142327-44-4

On July 23, 2009, Hashimoto, Kazuki; Katoda, Wataru; Takahashi, Kazuhiko; Kurimoto, Ayumu published a patent.Name: Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of adenine compounds. And the patent contained the following:

The title compounds I [A1 = (CH2)m; A2 = (CH2)n; R1 = alkyl; R2, R3 = H, alkyl; or NR2R3 = pyrrolidine, morpholine, piperidine, etc.; R4 = alkyl] are prepared by reacting (aminoalkyl)dihydropurinone derivatives with alkyl (3-formylphenyl)acetate in the presence of boron reducing agents. I are useful as pharmaceuticals (no data). Reaction of 6-amino-2-butoxy-9-(3-[(3-morpholin-4-ylpropyl)amino]propyl)-7,9-dihydro-8H-purin-8-one dimaleate with Me (3-formylphenyl)acetate in the presence of triethylamine and sodium triacetoxyborohydride gave Me (3-([[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl)phenyl)acetate. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Name: Methyl 2-(3-formylphenyl)acetate

The Article related to adenine derivative preparation pharmaceutical, aminobutoxyoxodihydropurinylpropylmorpholinylpropylaminomethylphenylacetate preparation, aminobutoxymorpholinylpropylaminopropyldihydropurinone reaction formylphenylacetate sodium triacetoxyborohydride, aminoalkyldihydropurinone derivative reaction formylphenylacetate boron reducing agent and other aspects.Name: Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 15, 2005, Constan, Alexander A.; Keshary, Prakash; Maclean, David B.; Paralkar, Vishwas M.; Roman, Doina; Thompson, David D.; Wright, Timothy M. published a patent.Electric Literature of 142327-44-4 The title of the patent was Preparation of heterocyclic compounds as EP2 selective receptor agonists for treating pulmonary hypertension and other conditions. And the patent contained the following:

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using the compounds I [A = SO2, CO; G = Ar, Ar(alkylene), ArCONH(alkylene), etc.; B = N, CH; Q = alkylene, X(alkylene), X(alkylene), etc.; Z = carboxy, alkoxycarbonyl, tetrazolyl, etc.; K = a bond, alkylene, thioalkylene, etc.; M = Ar3, Ar4SAr5, Ar4OAr5, etc.; Ar, Ar3-Ar5 = partially saturated or fully unsaturated 5-8 membered ring having 1-4 heteroatoms selected from O, S, N, or a bicyclic ring, tricycling ring, etc.; X = X = 5-6 membered aromatic ring optionally having 1-2 heteroatoms selected from O, N and S], an EP2 selective receptor agonists. Syntheses of representative compounds I and their intermediates are described in several examples. E.g., a 3-step synthesis of 7-[(4-butylbenzyl)-(pyridine-3-sulfonyl)amino]heptanoic acid, starting from Me 7-aminoheptanoate (preparation given) and 4-butylbenzaldehyde, was given. The compounds I were tested for binding to prostaglandin E2 receptors (data given for exemplified compounds I). The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Electric Literature of 142327-44-4

The Article related to heterocyclic compound ep2 receptor agonist therapeutic antihypertensive, pulmonary hypertension treatment ep2 receptor agonist heterocyclic compound, thiophenecarboxylate preparation ep2 receptor agonist therapeutic antihypertensive, pyridinesulfonylaminomethylphenylacetate preparation ep2 receptor agonist therapeutic antihypertensive and other aspects.Electric Literature of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 25, 1997, Berryman, Kent Alan; Doherty, Annette Marian; Edmunds, Jeremy John; Patt, William Chester; Plummer, Mark Stephen; Repine, Joseph Thomas published a patent.Quality Control of Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of 3,5-diphenyl-2(5H)-furanone derivatives as nonpeptide endothelin I antagonists. And the patent contained the following:

Novel nonpeptide antagonists of endothelin I represented by formula [I; R1 = (un)substituted C3-12 cycloalkyl, Ph substituted with 1-5 substituents, naphthyl or heteroaryl optionally substituted with 1-5 substituents; R2 = C1-12 linear or branched alkyl, C3-12 linear or branched cycloalkyl, aryl optionally substituted with 1-5 substituents, heteroaryl optionally substituted with 1-3 substituents; R3 = (un)substituted C1-12 linear or branched alkyl, (un)substituted C3-12 cycloalkyl, aryl optionally substituted with 1-5 substituents, heteroaryl optionally substituted with 1-3 substituents; R4 = OH, OR5, (CH2)nOR5; wherein R5 = (un)substituted C1-7 alkyl; X = O, S] or tautomeric open chain keto-acids forms thereof or pharmaceutically acceptable salt thereof are prepared Also described are pharmaceutical compositions of the above compounds, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmia, asthma, preeclampsia, atherosclerotic disorders including Raynaud’s disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prostatic hyperplasia (BPH), and diabetes. Thus, Me 2-benzoyl-2-phenylacetate derivative (II) and 3,4,5-trimethoxybenzladehyde were refluxed in the presence of NaOMe in MeOH for 18 h and the solution was treated with AcOH and refluxed an addnl. 72 h, followed by saponification of the product with 1N aqueous NaOH and acidification to give 28% I (X = O, R1 = Q, R2 = 3,4,5-trimethoxyphenyl, R3 = 4-methoxyphenyl, R4 = OH). The latter compound in vitro showed an antagonism of endothelin I-stimulated vasoconstriction in the rabbit femoral artery and sarafotoxin 6c-stimulated vasoconstriction in the rabbit pulmonary artery with pA2 values of 0.00025 and 0.34, resp. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Quality Control of Methyl 2-(3-formylphenyl)acetate

The Article related to acute renal failure, angina pectoris, antiarrhythmics, antiasthmatics, antiatherosclerotics, antidiabetic agents, antihypertensives, antitumor agents, benign prostatic hyperplasia, brain infarction, brain ischemia, cerebral artery spasm, chronic renal failure, cirrhosis, coronary restenosis, gastric mucosa (damage), heart failure and other aspects.Quality Control of Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics